Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Reply to "ESMO-MCBS v1.1: Statistical and Patient Relevant Shortcomings" by R. Emprechtinger et al.

Cherny NI, Dafni U, Piccart M, Latino NJ, Douillard JY, Bogaerts J, Karlis D, Zygoura P, Pentheroudakis G, Tabernero J, Zielinski C, de Vries EGE.

Ann Oncol. 2018 Apr 5. doi: 10.1093/annonc/mdy108. [Epub ahead of print] No abstract available.

PMID:
29659680
2.

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, Chiang C, Monos DS, Torigian DA, Nisenbaum HL, Michielin O, June CH, Levine BL, Powell DJ Jr., Gfeller D, Mick R, Dafni U, Zoete V, Harari A, Coukos G, Kandalaft LE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaao5931. doi: 10.1126/scitranslmed.aao5931.

PMID:
29643231
3.

RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.

Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE.

J Natl Cancer Inst. 2018 Mar 12. doi: 10.1093/jnci/djy029. [Epub ahead of print] No abstract available.

PMID:
29546378
4.

Association of p27 and cyclin D1 expression and benefit from adjuvant trastuzumab treatment in HER2-positive early breast cancer: a TransHERA study.

Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, De Azambuja E, Larsimont DP, Rojo F, Viale G, Toi M, Harbeck N, Pritchard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart M, Dowsett M.

Clin Cancer Res. 2018 Mar 12. pii: clincanres.3473.2017. doi: 10.1158/1078-0432.CCR-17-3473. [Epub ahead of print]

PMID:
29530933
5.

Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project.

Letovanec I, Finn S, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel EJ, Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernandez-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, Navarro A, Felip E, Warth A, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dienemann H, Dziadziuszko R, Vansteenkiste J, O'Brien C, Geiger T, Sherlock J, Schageman J, Dafni U, Kammler R, Kerr K, Thunnissen E, Stahel R, Peters S; European Thoracic Oncology Platform Lungscape Consortium.

J Thorac Oncol. 2018 Mar;13(3):413-425. doi: 10.1016/j.jtho.2017.11.117. Epub 2017 Nov 27.

PMID:
29191776
6.

Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project.

Kerr KM, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Finn S, Biernat W, Vliegen L, Losa JH, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Monkhorst K, Jantus Lewintre E, Tischler V, Clark C, Bertran-Alamillo J, Meldgaard P, Gately K, Wrona A, Vandenberghe P, Felip E, De Luca G, Savic S, Muley T, Smit EF, Dingemans AC, Priest L, Baas P, Camps C, Weder W, Polydoropoulou V, Geiger TR, Kammler R, Sumiyoshi T, Molina MA, Shames DS, Stahel RA, Peters S; ETOP Lungscape Consortium.

Ann Oncol. 2018 Jan 1;29(1):200-208. doi: 10.1093/annonc/mdx629.

PMID:
29186353
7.

Reply to the letter to the editor 'Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies'.

Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE.

Ann Oncol. 2018 Mar 1;29(3):774-775. doi: 10.1093/annonc/mdx747. No abstract available.

PMID:
29161364
8.

Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules.

Dafni U, Karlis D, Pedeli X, Bogaerts J, Pentheroudakis G, Tabernero J, Zielinski CC, Piccart MJ, de Vries EGE, Latino NJ, Douillard JY, Cherny NI.

ESMO Open. 2017 Oct 9;2(4):e000216. doi: 10.1136/esmoopen-2017-000216. eCollection 2017.

9.

Reply to the letter to the editor 'Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?' by Del Paggio.

Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE.

Ann Oncol. 2018 Feb 1;29(2):521-522. doi: 10.1093/annonc/mdx649. No abstract available.

PMID:
29045537
10.

ESMO-Magnitude of Clinical Benefit Scale version 1.1.

Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE.

Ann Oncol. 2017 Oct 1;28(10):2340-2366. doi: 10.1093/annonc/mdx310.

PMID:
28945867
11.

Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project.

Bubendorf L, Dafni U, Schöbel M, Finn SP, Tischler V, Sejda A, Marchetti A, Thunnissen E, Verbeken EK, Warth A, Sansano I, Cheney R, Speel EJM, Nonaka D, Monkhorst K, Hager H, Martorell M, Savic S, Kerr KM, Tan Q, Tsourti Z, Geiger TR, Kammler R, Schulze K, Das-Gupta A, Shames D, Peters S, Stahel RA; Lungscape Consortium.

Lung Cancer. 2017 Sep;111:143-149. doi: 10.1016/j.lungcan.2017.07.021. Epub 2017 Jul 22.

PMID:
28838386
12.

Reply to the letter to the editor 'Addressing the quality of the ESMO-MCBS' by Del Paggio.

Cherny NI, Dafni U, Bogaerts J, Pentheroudakis G, Tabernero J, Zielinski C, Piccart M, de Vries EGE.

Ann Oncol. 2017 Aug 1;28(8):2031-2032. doi: 10.1093/annonc/mdx200. No abstract available.

PMID:
28430861
13.

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.

Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA; BELIEF collaborative group.

Lancet Respir Med. 2017 May;5(5):435-444. doi: 10.1016/S2213-2600(17)30129-7. Epub 2017 Apr 10.

PMID:
28408243
14.

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.

Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF; EMPHASIS-lung Collaborative Group.

J Thorac Oncol. 2017 Apr;12(4):752-762. doi: 10.1016/j.jtho.2016.12.017. Epub 2016 Dec 23.

15.

ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers.

Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, Piccart MJ, Bogaerts J, Tabernero J, Latino NJ, de Vries EG.

ESMO Open. 2016 Oct 18;1(5):e000100. eCollection 2016. Review.

16.

Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015.

Rolfo C, Caglevic C, Bretel D, Hong D, Raez LE, Cardona AF, Oton AB, Gomez H, Dafni U, Vallejos C, Zielinski C.

ESMO Open. 2016 Jun 17;1(4):e000055. eCollection 2016. Review.

17.

Reply to the letter to the editor 'Utilisation of the ESMO-MCBS in practice of HTA' by Wild et al.

Cherny NI, Sullivan R, Dafni U, Bogaerts J, Kerst JM, Zielinski C, Piccart MJ, de Vries EG.

Ann Oncol. 2016 Nov;27(11):2136-2137. Epub 2016 Aug 29. No abstract available.

PMID:
27573563
18.

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EGE, Piccart MJ.

Ann Oncol. 2017 Nov 1;28(11):2901-2905. doi: 10.1093/annonc/mdw258. No abstract available.

PMID:
27604385
19.

Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.

Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, Long B, de Azambuja E, Sotiriou C, Viale G, Rüschoff J, Piccart MJ, Dowsett M, Michiels S, Leyland-Jones B.

JAMA Oncol. 2016 Aug 1;2(8):1040-7. doi: 10.1001/jamaoncol.2016.0339.

PMID:
27100299
20.

Selection of the primary end point in an observational cohort study.

Gómez G, Plana-Ripoll O, Dafni U.

J Epidemiol Community Health. 2016 Oct;70(10):950-3. doi: 10.1136/jech-2015-206656. Epub 2016 Apr 12. No abstract available.

PMID:
27072869
21.

VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside.

Arjaans M, Schröder CP, Oosting SF, Dafni U, Kleibeuker JE, de Vries EG.

Oncotarget. 2016 Apr 19;7(16):21247-58. doi: 10.18632/oncotarget.6918. Review.

22.

Reply to the letter to the editor 'The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice' by Hartmann and the letter 'Comment on ESMO Magnitude of Clinical Benefit Scale' by Muhonen et al.

Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EG, Piccart MJ.

Ann Oncol. 2016 Jan;27(1):203-5. doi: 10.1093/annonc/mdv502. Epub 2015 Oct 30. No abstract available.

PMID:
26519490
23.

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EG, Piccart MJ.

Ann Oncol. 2015 Aug;26(8):1547-73. doi: 10.1093/annonc/mdv249. Epub 2015 May 30. Erratum in: Ann Oncol. 2017 Nov 1;28(11):2901-2905.

PMID:
26026162
24.

Reply to D. Adkins et al.

Psyrri A, Economopoulou P, Dafni U.

J Clin Oncol. 2015 Apr 1;33(10):1225-6. doi: 10.1200/JCO.2014.59.9449. Epub 2015 Feb 23. No abstract available.

PMID:
25713435
25.

Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters.

Peters S, Weder W, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, O'Byrne KJ, Wrona A, Vansteenkiste J, Felip E, Marchetti A, Savic S, Lu S, Smit E, Dingemans AM, Blackhall FH, Baas P, Camps C, Rosell R, Stahel RA; ETOP Lungscape Investigators.

J Thorac Oncol. 2014 Nov;9(11):1675-84. doi: 10.1097/JTO.0000000000000320.

26.

Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.

Blackhall FH, Peters S, Bubendorf L, Dafni U, Kerr KM, Hager H, Soltermann A, O'Byrne KJ, Dooms C, Sejda A, Hernández-Losa J, Marchetti A, Savic S, Tan Q, Thunnissen E, Speel EJ, Cheney R, Nonaka D, de Jong J, Martorell M, Letovanec I, Rosell R, Stahel RA.

J Clin Oncol. 2014 Sep 1;32(25):2780-7. doi: 10.1200/JCO.2013.54.5921. Epub 2014 Jul 28.

PMID:
25071109
27.

Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial.

Fountzilas G, Dafni U, Papadimitriou C, Timotheadou E, Gogas H, Eleftheraki AG, Xanthakis I, Christodoulou C, Koutras A, Papandreou CN, Papakostas P, Miliaras S, Markopoulos C, Dimitrakakis C, Korantzopoulos P, Karanikiotis C, Bafaloukos D, Kosmidis P, Samantas E, Varthalitis I, Pavlidis N, Pectasides D, Dimopoulos MA.

BMC Cancer. 2014 Jul 15;14:515. doi: 10.1186/1471-2407-14-515.

28.

Combining cetuximab with chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: is more better?

Psyrri A, Dafni U.

J Clin Oncol. 2014 Sep 20;32(27):2929-31. No abstract available.

PMID:
25002730
29.

In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.

Vassilakopoulou M, Togun T, Dafni U, Cheng H, Bordeaux J, Neumeister VM, Bobos M, Pentheroudakis G, Skarlos DV, Pectasides D, Kotoula V, Fountzilas G, Rimm DL, Psyrri A.

PLoS One. 2014 Jun 26;9(6):e99131. doi: 10.1371/journal.pone.0099131. eCollection 2014.

30.

Phase II design with sequential testing of hypotheses within each stage.

Poulopoulou S, Karlis D, Yiannoutsos CT, Dafni U.

J Biopharm Stat. 2014;24(4):768-84. doi: 10.1080/10543406.2014.900784.

PMID:
24697358
31.

Second line treatment for EGFR wild-type advanced NSCLC: the jury is still out.

Dafni U, Karlis D, Smit E, Peters S.

Lung Cancer. 2014 Jun;84(3):314-5. doi: 10.1016/j.lungcan.2014.03.012. Epub 2014 Mar 15. No abstract available.

PMID:
24685307
32.

Informed choice of composite end points in cardiovascular trials.

Gómez G, Gómez-Mateu M, Dafni U.

Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):170-8. doi: 10.1161/CIRCOUTCOMES.113.000149. Epub 2014 Jan 14.

33.

HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab.

Zabaglo L, Stoss O, Rüschoff J, Zielinski D, Salter J, Arfi M, Bradbury I, Dafni U, Piccart-Gebhart M, Procter M, Dowsett M; HERA Trial Study Team.

Ann Oncol. 2013 Nov;24(11):2761-6. doi: 10.1093/annonc/mdt275. Epub 2013 Jul 25.

PMID:
23894039
34.

Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.

Fountzilas G, Dafni U, Bobos M, Kotoula V, Batistatou A, Xanthakis I, Papadimitriou C, Kostopoulos I, Koletsa T, Tsolaki E, Televantou D, Timotheadou E, Koutras A, Klouvas G, Samantas E, Pisanidis N, Karanikiotis C, Sfakianaki I, Pavlidis N, Gogas H, Linardou H, Kalogeras KT, Pectasides D, Dimopoulos MA.

BMC Cancer. 2013 Mar 28;13:163. doi: 10.1186/1471-2407-13-163.

35.

Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03).

Bamias A, Dafni U, Karadimou A, Timotheadou E, Aravantinos G, Psyrri A, Xanthakis I, Tsiatas M, Koutoulidis V, Constantinidis C, Hatzimouratidis C, Samantas E, Visvikis A, Chrisophos M, Stravodimos K, Deliveliotis C, Eleftheraki A, Pectasides D, Fountzilas G, Dimopoulos MA.

Ann Oncol. 2013 Apr;24(4):1011-7. doi: 10.1093/annonc/mds583. Epub 2012 Nov 7.

PMID:
23136231
36.

Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.

Fountzilas G, Dafni U, Bobos M, Batistatou A, Kotoula V, Trihia H, Malamou-Mitsi V, Miliaras S, Chrisafi S, Papadopoulos S, Sotiropoulou M, Filippidis T, Gogas H, Koletsa T, Bafaloukos D, Televantou D, Kalogeras KT, Pectasides D, Skarlos DV, Koutras A, Dimopoulos MA.

PLoS One. 2012;7(6):e37946. doi: 10.1371/journal.pone.0037946. Epub 2012 Jun 5.

37.

Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.

Gogas H, Dafni U, Karina M, Papadimitriou C, Batistatou A, Bobos M, Kalofonos HP, Eleftheraki AG, Timotheadou E, Bafaloukos D, Christodoulou C, Markopoulos C, Briasoulis E, Papakostas P, Samantas E, Kosmidis P, Stathopoulos GP, Karanikiotis C, Pectasides D, Dimopoulos MA, Fountzilas G.

Breast Cancer Res Treat. 2012 Apr;132(2):609-19. doi: 10.1007/s10549-011-1913-4. Epub 2011 Dec 21.

PMID:
22187126
38.

The MARS feasibility trial: conclusions not supported by data.

Weder W, Stahel RA, Baas P, Dafni U, de Perrot M, McCaughan BC, Nakano T, Pass HI, Robinson BW, Rusch VW, Sugarbaker DJ, van Zandwijk N.

Lancet Oncol. 2011 Nov;12(12):1093-4; author reply 1094-5. doi: 10.1016/S1470-2045(11)70307-2. No abstract available.

PMID:
22041539
39.

Landmark analysis at the 25-year landmark point.

Dafni U.

Circ Cardiovasc Qual Outcomes. 2011 May;4(3):363-71. doi: 10.1161/CIRCOUTCOMES.110.957951. Review.

40.

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R; Herceptin Adjuvant (HERA) Trial Study Team.

Lancet Oncol. 2011 Mar;12(3):236-44. doi: 10.1016/S1470-2045(11)70033-X. Epub 2011 Feb 25.

PMID:
21354370
41.

Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial.

Gogas H, Dafni U, Koon H, Spyropoulou-Vlachou M, Metaxas Y, Buchbinder E, Pectasides E, Tsoutsos D, Polyzos A, Stratigos A, Markopoulos C, Panagiotou P, Fountzilas G, Castana O, Skarlos P, Atkins MB, Kirkwood JM.

J Transl Med. 2010 Nov 3;8:108. doi: 10.1186/1479-5876-8-108.

42.

Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon.

Gogas H, Kirkwood JM, Falk CS, Dafni U, Sondak VK, Tsoutsos D, Stratigos A, Markopoulos C, Pectasides D, Spyropoulou-Vlachou M.

Cancer. 2010 Sep 15;116(18):4326-33. doi: 10.1002/cncr.25211.

43.

Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Liu WT, Toi M, Coombes RC, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, van Veldhuisen DJ, Piccart-Gebhart MJ.

J Clin Oncol. 2010 Jul 20;28(21):3422-8. doi: 10.1200/JCO.2009.26.0463. Epub 2010 Jun 7.

PMID:
20530280
44.

Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.

Markopoulos C, Tzoracoleftherakis E, Polychronis A, Venizelos B, Dafni U, Xepapadakis G, Papadiamantis J, Zobolas V, Misitzis J, Kalogerakos K, Sarantopoulou A, Siasos N, Koukouras D, Antonopoulou Z, Lazarou S, Gogas H.

Breast Cancer Res. 2010;12(2):R24. doi: 10.1186/bcr2565. Epub 2010 Apr 16.

45.

Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis.

Pectasides E, Egloff AM, Sasaki C, Kountourakis P, Burtness B, Fountzilas G, Dafni U, Zaramboukas T, Rampias T, Rimm D, Grandis J, Psyrri A.

Clin Cancer Res. 2010 Apr 15;16(8):2427-34. doi: 10.1158/1078-0432.CCR-09-2658. Epub 2010 Apr 6.

46.

Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model.

Bamias A, Karadimou A, Lampaki S, Lainakis G, Malettou L, Timotheadou E, Papazisis K, Andreadis C, Kontovinis L, Anastasiou I, Stravodimos K, Xanthakis I, Skolarikos A, Christodoulou C, Syrigos K, Papandreou C, Razi E, Dafni U, Fountzilas G, Dimopoulos MA.

BMC Cancer. 2010 Feb 18;10:45. doi: 10.1186/1471-2407-10-45.

47.

Alexithymia is positively associated with the outcome of in vitro fertilization (IVF) treatment.

Kakatsaki D, Vaslamatzis G, Chatziandreou M, Anastasiadi K, Dafni U, Tzavara C, Stefanidis K, Loutradis D, Antsaklis A.

Psychol Rep. 2009 Oct;105(2):522-32.

PMID:
19928613
48.

Fifteen-year trends in metastatic breast cancer survival in Greece.

Dafni U, Grimani I, Xyrafas A, Eleftheraki AG, Fountzilas G.

Breast Cancer Res Treat. 2010 Feb;119(3):621-31. doi: 10.1007/s10549-009-0630-8.

PMID:
19915976
49.

Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer.

Briasoulis E, Pappas P, Puozzo C, Tolis C, Fountzilas G, Dafni U, Marselos M, Pavlidis N.

Clin Cancer Res. 2009 Oct 15;15(20):6454-61. doi: 10.1158/1078-0432.CCR-09-0970. Epub 2009 Oct 6.

50.

Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy.

Markopoulos C, Dafni U, Misitzis J, Zobolas V, Tzoracoleftherakis E, Koukouras D, Xepapadakis G, Papadiamantis J, Venizelos B, Antonopoulou Z, Gogas H.

Breast Cancer Res. 2009;11(3):R35. doi: 10.1186/bcr2320. Epub 2009 Jun 16.

Supplemental Content

Support Center